Implications of the serine protease HtrA1 in amyloid precursor protein processing
Author(s) -
Sandra Grau,
Alfonso Baldi,
Rossana Bussani,
Xiaodan Tian,
Raluca Ştefănescu,
Michael Przybylski,
Peter J. Richards,
Simon A. Jones,
Viji Shridhar,
Tim Clausen,
Michael Ehrmann
Publication year - 2005
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0501823102
Subject(s) - proteases , serine protease , amyloid precursor protein , serine , zymogen , protein precursor , pdz domain , biology , p3 peptide , protease , amyloid (mycology) , biochemistry , microbiology and biotechnology , alzheimer's disease , enzyme , disease , medicine , botany , pathology
The defining features of the widely conserved HtrA (high temperature requirement) family of serine proteases are the combination of a catalytic protease domain with one or more C-terminal PDZ domains and reversible zymogen activation. Even though HtrAs have previously been implicated in protein quality control and various diseases, including cancer, arthritis, and neuromuscular disorder, the biology of the human family members is not well understood. Our data suggest that HtrA1 is directly involved in the beta-amyloid pathway as it degrades various fragments of amyloid precursor protein while an HtrA1 inhibitor causes accumulation of Abeta in astrocyte cell culture supernatants. Furthermore, HtrA1 colocalizes with beta-amyloid deposits in human brain samples. Potential implications in Alzheimer's disease are discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom